Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuendez M, Cordero E, Topczewski TE, Ferres-Pijoan A, González J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J. Bonfill-Teixidor E, et al. Among authors: eckmann j. Cancer Res. 2022 Jul 18;82(14):2552-2564. doi: 10.1158/0008-5472.CAN-21-4152. Cancer Res. 2022. PMID: 35584009
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Wichmann J, Rynn C, Friess T, Petrig-Schaffland J, Kornacker M, Handl C, Emmenegger J, Eckmann J, Herting F, Frances N, Hunziker D, Krummenacher D, Rüttinger D, Ribeiro A, Bacac M, Brigo A, Hewings DS, Dummer R, Levesque MP, Schnetzler G, Martoglio B, Bischoff JR, Pettazzoni P. Wichmann J, et al. Among authors: eckmann j. Clin Cancer Res. 2022 Feb 15;28(4):770-780. doi: 10.1158/1078-0432.CCR-21-2761. Clin Cancer Res. 2022. PMID: 34782366
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors.
Scheuplein F, Renner F, Campbell JE, Campbell R, De Savi C, Eckmann J, Fischer H, Ge J, Green L, Jakob P, Kim JL, Kinkema C, McGinn K, Medina R, Müller A, Perez N, Perola E, Timsit Y, Traore T, Hopfer U, Tyanova S, Tzouros M, Wang R, Woessner R, Dorsch M, Bischoff JR. Scheuplein F, et al. Among authors: eckmann j. Front Immunol. 2024 Oct 21;15:1411395. doi: 10.3389/fimmu.2024.1411395. eCollection 2024. Front Immunol. 2024. PMID: 39502695 Free PMC article.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Solomon I, et al. Among authors: eckmann j. Nat Cancer. 2020 Dec;1(12):1153-1166. doi: 10.1038/s43018-020-00133-0. Epub 2020 Nov 9. Nat Cancer. 2020. PMID: 33644766 Free PMC article.
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, Gottwald S, Rae R, Lechner S, Bayer C, Dekempe Q, Osl F, Carrié N, Kassem S, Lorenz S, Christopeit T, Carpy A, Bujotzek A, Bröske AE, Dekhtiarenko I, Attig J, Kunz L, Cremasco F, Adelfio R, Fertig G, Dengl S, Gassner C, Bormann F, Kirstenpfad C, Kraft TE, Diggelmann S, Knobloch M, Hage C, Feddersen R, Heidkamp G, Pöschinger T, Mayoux ML, Bernasconi L, Dumontet C, Prosper F, Martinet L, Leclair S, Xu W, Paiva B, Klein C, Umaña P. Eckmann J, et al. Blood. 2024 Oct 30:blood.2024025987. doi: 10.1182/blood.2024025987. Online ahead of print. Blood. 2024. PMID: 39476124
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Geiger M, Stubenrauch KG, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, Lauer ME, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein C. Geiger M, et al. Among authors: eckmann j. Nat Commun. 2020 Jun 24;11(1):3196. doi: 10.1038/s41467-020-16838-w. Nat Commun. 2020. PMID: 32581215 Free PMC article.
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Sam J, Hofer T, Kuettel C, Claus C, Thom J, Herter S, Georges G, Korfi K, Lechmann M, Eigenmann MJ, Marbach D, Jamois C, Lechner K, Krishnan SM, Gaillard B, Marinho J, Kronenberg S, Kunz L, Wilson S, Briner S, Gebhardt S, Varol A, Appelt B, Nicolini V, Speziale D, Bez M, Bommer E, Eckmann J, Hage C, Limani F, Jenni S, Schoenle A, Le Clech M, Vallier JP, Colombetti S, Bacac M, Gasser S, Klein C, Umaña P. Sam J, et al. Among authors: eckmann j. Blood. 2024 May 23;143(21):2152-2165. doi: 10.1182/blood.2023023381. Blood. 2024. PMID: 38437725 Free PMC article.
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
Kerns SJ, Belgur C, Petropolis D, Kanellias M, Barrile R, Sam J, Weinzierl T, Fauti T, Freimoser-Grundschober A, Eckmann J, Hage C, Geiger M, Ng PR, Tien-Street W, Manatakis DV, Micallef V, Gerard R, Bscheider M, Breous-Nystrom E, Schneider A, Giusti AM, Bertinetti-Lapatki C, Grant HS, Roth AB, Hamilton GA, Singer T, Karalis K, Moisan A, Bruenker P, Klein C, Bacac M, Gjorevski N, Cabon L. Kerns SJ, et al. Among authors: eckmann j. Elife. 2021 Aug 11;10:e67106. doi: 10.7554/eLife.67106. Elife. 2021. PMID: 34378534 Free PMC article.
61 results